SCHEMBL3679465

SCHEMBL3679465

N=C(N)SCc1ccccc1-c1ccccc1CSC(=N)N

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 11/20 0.67
▸ HTT P42858 5/20 0.67
▸ SMN1; SMN2 Q16637 4/20 0.67
▸ LMNA P02545 3/20 0.67
▸ TAAR1 Q96RJ0 2/20 0.67
▸ HPGD P15428 2/20 0.62
▸ NOS1 P29475 2/20 0.61
▸ NOS3 P29474 1/20 0.61
▸ NOS2 P35228 1/20 0.61
▸ SLC11A2 P49281 2/20 0.56
▸ MAPT P10636 2/20 0.52
▸ TP53 P04637 2/20 0.49
▸ CYP3A4 P08684 2/20 0.49
▸ CYP1A2 P05177 1/20 0.49
▸ CYP2D6 P10635 1/20 0.49
▸ HIF1A Q16665 1/20 0.49
▸ KDM4E B2RXH2 1/20 0.47
▸ ALDH1A1 P00352 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2812696 0.89 IDO1 (0.74) IDO1HTTSMN1; SMN2LMNATAAR1
SCHEMBL12433147 0.89 IDO1 (0.59) IDO1HTTSMN1; SMN2LMNATAAR1
Bromide SCHEMBL2810146 0.87 IDO1 (0.71) IDO1HTTSMN1; SMN2LMNATAAR1
Hydrochloric Acid SCHEMBL22263112 0.87 IDO1 (0.75) IDO1HTTSMN1; SMN2LMNATAAR1
SCHEMBL3684767 0.84 HTT (0.59) IDO1HTTSMN1; SMN2LMNATAAR1
Bromide SCHEMBL4018130 0.82 HTT (0.57) IDO1HTTSMN1; SMN2LMNATAAR1
SCHEMBL3690551 0.81 HTT (0.65) IDO1HTTSMN1; SMN2LMNATAAR1
SCHEMBL13007579 0.80 IDO1 (1.00) IDO1HTTSMN1; SMN2LMNATAAR1
SCHEMBL12433171 0.80 IDO1 (0.62) IDO1HTTSMN1; SMN2LMNATAAR1
SCHEMBL2206997 0.80 IDO1 (0.62) IDO1HTTSMN1; SMN2LMNATAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010005851-A1 COMBINATION THERAPY FOR TREATING IRON DISORDERS XENON PHARMACEUTICALS INC. (CA) 2010-01-14 — — WO claimed
EP-2061754-A1 BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS XENON PHARMACEUTICALS INC. (CA) 2009-05-27 — — EP claimed
WO-2008115999-A1 BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS XENON PHARMACEUTICALS INC. (CA) 2008-09-25 — — WO claimed
US-20080234384-A1 BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS XENON PHARMACEUTICALS INC. (CA) 2008-09-25 — — US claimed
WO-2010005851-A1 COMBINATION THERAPY FOR TREATING IRON DISORDERS XENON PHARMACEUTICALS INC. (CA) 2010-01-14 — — WO disclosed
EP-2061754-A1 BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS XENON PHARMACEUTICALS INC. (CA) 2009-05-27 — — EP disclosed
WO-2008115999-A1 BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS XENON PHARMACEUTICALS INC. (CA) 2008-09-25 — — WO disclosed
US-20080234384-A1 BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS XENON PHARMACEUTICALS INC. (CA) 2008-09-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234384-A1 BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS FECH, SLC10A1, SLC40A1 IDO1 269/4885HTT 1363/4885SMN1; SMN2 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback